A Mixed Bag

Times are still difficult for many biotechs, but Ed Silverman writes at Pharmalot that the situation is actually a bit variable. Drawing on a report from consulting firm BDO, Silverman notes that biotech firms spent slightly more on R&D in 2011 than in 2010, though he adds that while large biotechs reported about 33 percent increase in revenue, smaller biotechs have not seen such large gains, reporting 12 percent decline in revenue.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

CRO Future

Guideline Change

Provision Cost

Quick Exit

Access and Authority

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."